Coherus gains on PK/PD readout for Neulasta biosimilar

Coherus BioSciences Inc. (NASDAQ:CHRS) gained $4.71 (27%) to $21.93 on Monday after it said CHS-1701 met the co-primary pharmacodynamic and pharmacokinetic endpoints in a Phase I study that compared the biosimilar with its reference product, neutropenia drug Neulasta pegfilgrastim from Amgen Inc. (NASDAQ:AMGN).

Coherus expects to submit a BLA to FDA this quarter for CHS-1701. ...